Nanordica Medical

ADVANCED ANTIBACTERIAL WOUND DRESSING *(AAWD)*

nanordica.com

POWERED BY PREMOTIV® nanotechnology

Safer wound care with Premotiv® dressing

supporting faster wound closure



Premotiv® wound dressing is designed to **prevent** infection & **promote** wound closure.

PREMOTIV® nanotechnology

Premotiv® wound dressing is a sterile single-use dressing, in which wound contact layer is made of natural silk nanofibers containing synergistic antibacterial nanoparticles (NP).

- ✔ Supports wound closure
- ✔ Reduces bacterial load
- ✔ Enables atraumatic dressing change

INDICATIONS:

- Diabetic foot ulcers
- Surgical wounds
- Traumatic wounds
- Infected wounds
- Wounds at risk of infection

non-infected DFUs

The lifetime risk of diabetic foot ulcers (DFUs) is 19-34% among the ~500 million people worldwide living with diabetes.

~55% of diabetic ulcers become infected

~20% of infected DFUs result in amputation

~50% of amputees die in 5 years

AVAILABLE in Q4 2026

Please let us know if you want to test the product meelis@nanordica.com

VER03 29.04.2026

Premotiv® wound dressing has high efficacy & high safety

In vitro safety and efficacy of wound dressings with antimicrobial agents:



- A quantitative log reduction assay *in vitro* with bacterial suspension demonstrated that Premotiv® wound dressing has the highest antibacterial activity.
- *In vitro* cytotoxicity testing demonstrated that Premotiv® wound dressing is less toxic to human cells compared to other antibacterial dressings.

** Lowest dilution factor of a dressing extract to maintain >70% human keratinocyte HaCaT cell viability in vitro. All experiments complied with ISO 10993-5:2009*

*** Log reduction of Staphylococcus aureus, in vitro comparison to non-antibacterial dressing after 1 day*

CHX - Chlorhexidin, NP - nanoparticles, CuAgNP - Premotiv® wound dressing

Clinical validation supports the Premotiv® approach

A randomized controlled trial at the North Estonia Medical Centre included 30 patients with diabetic foot ulcers, randomly assigned to either silver ion (Ag+) wound dressings or Nanordica AAWD with Premotiv® nanotechnology.

Both groups were treated for one week with three dressing changes. Efficacy was measured by wound area reduction, bacterial load, and quality of life; safety by adverse events.

Results after 1-week active treatment:

	Nanordica Premotiv®	Ag+ dressing
Wound area reduction	43%	13%
Bacterial load	Stable	Increased
Quality of life	Improved	No change

Compared to the silver-based wound dressing, Nanordica wound dressing showed:

✔ Faster reduction in wound area size



**p< 0,05*

✔ Bacterial count in wound did not increase



**p< 0,05*

Premotiv® wound dressing was more effective in eliminating signs of wound infection such as redness and swelling.

Patient stories

A 65-year-old patient with obesity and hypertension presented with a year-old recurring diabetic foot ulcer (DFU). Following one week of using Premotiv® wound dressings, significant reduction in wound area size and complete re-epithelialization were observed during the 42-day period.

A 54-year-old patient with a history of myotonic dystrophy type 1 and hypertension underwent amputation of the first toe on his right foot seven years prior to the trial.

Four months before the trial, an unhealing ulcer appeared at the surgical site, characterized by continuous discharge and bleeding. Following one week of using Premotiv® dressings, exudate production decreased, and bleeding stopped during the 42-day period.

Five months later, the patient showed a significant decrease in wound size and discharge production, indicating positive progress in healing.

Nanordica Premotiv® wound dressing is evidence-based & clinically tested.
www.nanordica.com

Read the publication at
Journal of Wound Care